Randomized Sitagliptin Withdrawal Study (MK-0431-845)

NCT02738879 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

746

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Sitagliptin
DRUG: Placebo to sitagliptin
DRUG: Metformin
DRUG: Metformin XR
DRUG: Insulin glargine

Sponsor

Merck Sharp & Dohme LLC